Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2 study of lenalidomide added to standard induction and post-remission therapy in newly diagnosed AML or high-risk MDS (age 18–65)
2013-002843-26Phase 2Active
- Sponsor
- HOVON
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lenalidomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by HOVON. Primary endpoint: Primary endpoint Part A run-in. Started Nov 2013; status: active.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2013-002843-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002843-26.